Section Arrow
Quote
BOLT.NASDAQ
- Bolt Biotherapeutics Inc
Quotes are at least 15-min delayed:2026/04/15 15:35 EDT
Regular Hours
Last
 5.015
+0.275 (+5.80%)
Day High 
5.015 
Prev. Close
4.74 
1-M High
5.1311 
Volume 
8.35K 
Bid
4.9
Ask
5.13
Day Low
4.66 
Open
4.66 
1-M Low
4.03 
Market Cap 
9.11M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 4.6 
20-SMA 4.53 
50-SMA 4.7 
52-W High 7.35 
52-W Low 0.26 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-17.85/-9.87
Enterprise Value
29.24M
Balance Sheet
Book Value Per Share
13.79
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
7.70M
Operating Revenue Per Share
3.53
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
IMMPImmutep Limited0.6+0.2852+90.60%-- 
LIMNLiminatus Pharma Inc0.1923+0.0125+6.95%-- 
PPCBPropanc Biopharma Inc0.1117+0.0142+14.56%0PE
ALLOAllogene Therapeutics2.08-0.2-8.77%-- 
CUECue Biopharma0.6606+0.2226+50.82%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.